Related Experiment Video

Updated: Jun 27, 2026

Laser-Induced Action Potential-Like Measurements of Cardiomyocytes on Microelectrode Arrays for Increased Predictivity of Safety Pharmacology
10:41

Laser-Induced Action Potential-Like Measurements of Cardiomyocytes on Microelectrode Arrays for Increased Predictivity of Safety Pharmacology

Published on: September 13, 2022

Ivabradine: pharmacodynamic aspects of its clinical use

Juliane Stieber1

  • 1Institute for Experimental and Clinical Pharmacology and Toxicology, Friedrich-Alexander-University, Erlangen-Nuremberg, Germany. stieber@pharmakologie.uni-erlangen.de

Methods and Findings in Experimental and Clinical Pharmacology
|December 18, 2008
PubMed

Insights

Ivabradine effectively lowers heart rate by inhibiting the If pacemaker current, offering a favorable alternative to beta-blockers for chronic stable angina. Clinical data suggest it

Area of Science:

  • Cardiology
  • Pharmacology
  • Clinical Medicine

Background:

  • Ivabradine is approved for chronic stable angina when beta-blockers are contraindicated or not tolerated.
  • It functions by selectively inhibiting the If pacemaker current in the sinoatrial node.
  • Compared to other heart rate-lowering agents, ivabradine shows a potentially lower incidence of adverse reactions.

Purpose of the Study:

  • To review experimental and preclinical data on ivabradine.
  • To investigate the potential and limitations of its clinical application.
  • To assess its role as a first-choice agent for heart rate reduction.

Main Methods:

  • Evaluation of experimental and preclinical studies.
  • Analysis of clinical trial data.
  • Assessment of pharmacodynamic properties and clinical consequences.

Main Results:

  • Ivabradine effectively lowers heart rate via If current inhibition.
  • Experimental studies identified potential off-target effects at high concentrations.
  • Clinical studies indicate no adverse consequences at recommended doses with strict contraindication adherence.

Conclusions:

  • Ivabradine presents a favorable profile for pure heart rate-lowering therapy.
  • Potential unfavorable pharmacodynamic properties do not manifest clinically under recommended usage.
  • It may become a preferred treatment option for specific patient populations.

Related Concept Videos

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Pharmacodynamics: Overview and Principles01:21

Pharmacodynamics: Overview and Principles

Pharmacodynamics is a scientific field that delves into drugs' intricate biochemical, cellular, and physiological effects on the human body. The study of pharmacodynamics helps us understand how drugs interact with the body and elicit various responses.
Most drugs' effects result from their interactions with drug receptors or targets within the body. These interactions trigger specific responses at the cellular or systemic level. Drug receptors can be found on the surfaces of cells or within...
Depolarizing Blockers: Pharmocokinetics01:19

Depolarizing Blockers: Pharmocokinetics

Depolarizing blockers are administered through intravenous injection. Succinylcholine is the most common choice of depolarizing blockers in emergency clinical practices. Although they have a rapid onset, they readily diffuse away from the motor end plate into the extracellular fluid. They are metabolized by enzymes such as liver butyrylcholinesterase and plasma pseudocholinesterases. This produces a short duration of action, typically 5-10 minutes long, unlike nondepolarizing blockers, which...